Immunotherapy in Melanoma


The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Latest News

Peter Mohr, MD
Adjuvant Nivolumab Approved in Europe for Completely Resected Stage IIB or IIC Melanoma

August 22nd 2023

The European Commission has approved single-agent nivolumab for use in the adjuvant treatment of adult and adolescent patients aged 12 years or older who have stage IIB or IIC melanoma and who have undergone complete resection.

Pembrolizumab in Advanced Melanoma | Image Credit: © SciePro -
Pembrolizumab Elicits Long-Term Survival Benefit in Advanced Melanoma

August 17th 2023

Marjorie Green, MD
mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

July 26th 2023

Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma

July 21st 2023

Jason Luke, MD, FACP
Luke Breaks Down Key Clinical Trial Updates From the 2023 ASCO Annual Meeting

July 17th 2023

Video Series
Video Interviews

More News